Vanderbilt University Medical Center: Trial Combines Novel Therapies for Head and Neck Cancer
April 28, 2023
April 28, 2023
NASHVILLE, Tennessee, April 28 (TNSres) -- Vanderbilt University Medical Center issued the following news:
Vanderbilt-Ingram Cancer Center is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
This novel vaccine, PVX7, is made by PapiVax Biotech Inc., and the immunotherapy is pembrolizumab made by Merck. The combination is intended t . . .
Vanderbilt-Ingram Cancer Center is launching a clinical trial that pairs an experimental vaccine with an established immunotherapy for recurrent, human papilloma virus (HPV)-related oropharyngeal cancer of the head and neck.
This novel vaccine, PVX7, is made by PapiVax Biotech Inc., and the immunotherapy is pembrolizumab made by Merck. The combination is intended t . . .